NERVGEN PHARMA CORP. (NGEN)
About NERVGEN PHARMA CORP.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $197.5M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $197.5M
- Shares outstanding
- 121.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 25, 2019
Nervgen Pharma Corp. (NGEN) Stock Price
- Trading 73% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NERVGEN PHARMA CORP..
Write a review
News about NERVGEN PHARMA CORP.
News & sentiment via Polygon.io
Nervgen Pharma Corp.: frequently asked questions
Is Nervgen Pharma Corp. an American company?
Nervgen Pharma Corp. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Nervgen Pharma Corp. publicly traded?
Yes — Nervgen Pharma Corp. is a publicly traded company. Its stock trades under the ticker symbol NGEN on the NASDAQ.
What does Nervgen Pharma Corp. do?
Nervgen Pharma Corp. is an American Pharmaceuticals company in the Health & Beauty sector.
